These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 3112563

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities.
    König SA, Siemes H, Bläker F, Boenigk E, Gross-Selbeck G, Hanefeld F, Haas N, Köhler B, Koelfen W, Korinthenberg R.
    Epilepsia; 1994; 35(5):1005-15. PubMed ID: 7925143
    [Abstract] [Full Text] [Related]

  • 23. Non-fatal and fatal liver failure associated with valproic acid.
    Schmid MM, Freudenmann RW, Keller F, Connemann BJ, Hiemke C, Gahr M, Kratzer W, Fuchs M, Schönfeldt-Lecuona C.
    Pharmacopsychiatry; 2013 Mar; 46(2):63-8. PubMed ID: 22915484
    [Abstract] [Full Text] [Related]

  • 24. Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantation.
    Bell EA, Shaefer MS, Markin RS, Wood RP, Langnas AN, Stratta RJ, Shaw BW.
    Ann Pharmacother; 1992 Jan; 26(1):18-21. PubMed ID: 1606338
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H, Nau H, Schultze K, Wittfoht W, Drews E, Penzien J, Seidel U.
    Epilepsia; 1993 Jan; 34(2):332-46. PubMed ID: 8453944
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC.
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Markedly increased omega-oxidation of valproate in fulminant hepatic failure.
    Kuhara T, Inoue Y, Matsumoto M, Shinka T, Matsumoto I, Kawahara N, Sakura N.
    Epilepsia; 1990 May; 31(2):214-7. PubMed ID: 2108017
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
    Kondo T, Kaneko S, Otani K, Ishida M, Hirano T, Fukushima Y, Muranaka H, Koide N, Yokoyama M.
    Epilepsia; 1992 May; 33(1):172-7. PubMed ID: 1733753
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Treatment gaps of epilepsy and retention rates of sodium valproate in rural Guangxi, China.
    Huang DH, Zheng JO, Chen J, Yu L.
    Genet Mol Res; 2014 Aug 15; 13(3):6202-12. PubMed ID: 25158247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.